Inomagen
Chicago, US · Founded 2014 · 1 known investors
Inomagen Therapeutics develops a non-viral gene therapy delivered via a single-dose, minimally invasive procedure to target the underlying mechanisms of atrial fibrillation. The company operates under an exclusive license from Northwestern University and is based in a biotech incubator in Chicago.
Founders & leadership
Inomagen was founded in 2014 by Rishi Arora.
Board
MP
Marc PennBoard director
JR
James R. VoglerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$540K disclosed across 3 rounds · 2014–2025
▶$140KraisedJun 2025 · 4 investors · BiotechnologyRule 506(c)
▶$140KraisedJun 2025 · 4 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Rishi AroraExecutive Officer, Director
- Marc PennDirector
- James R. VoglerDirector
- Offering amount
- $3.8M
- Amount sold
- $140K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$200KraisedApr 2024 · 4 investors · BiotechnologyRule 506(b)
▶$200KraisedApr 2024 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rishi AroraExecutive Officer, Director
- James R. VoglerDirector
- Marc PennDirector
- Offering amount
- $6.6M
- Amount sold
- $200K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedNov 2014 · 8 investors · BiotechnologyRule 506(b)
▶$200KraisedNov 2014 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rishi AroraExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $200K
- Minimum investment
- $25K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Biogen Idec10 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Regeneron NASDAQ: REGN www.regeneron.com8 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Orogentx6 shared keywordsOrogen Therapeutics uses AI and machine learning to accelerate drug discovery, focusing on small molecule candidates for immuno-inflammatory diseases. The company combines computational chemistry, DNA-encoded library technology, and medicinal expertise to develop novel therapeutic medicines.
Companies competing with Inomagen for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Inomagen do?
- Inomagen Therapeutics develops a non-viral gene therapy delivered via a single-dose, minimally invasive procedure to target the underlying mechanisms of atrial fibrillation. The company operates under an exclusive license from Northwestern University and is based in a biotech incubator in Chicago.
- Who founded Inomagen?
- Inomagen was founded by Rishi Arora in 2014.
- Who are Inomagen's investors?
- Inomagen's investors include Portal Innovations.
- How much funding has Inomagen raised?
- Inomagen has disclosed $540K raised across 3 rounds.
- Where is Inomagen headquartered?
- Inomagen is headquartered in Chicago, US.